Viridian Therapeutics, Inc.
VRDNNASDAQHealthcare● Active
$15.73
$-0.05(-0.32%)
Market Cap$1.4B
P/E Ratio—
52W High$34.29
52W Low$13.18
Viridian Therapeutics, Inc. (VRDN) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · VRDN · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($342.60M) | ($269.95M) | ($237.73M) | ($129.87M) | ($79.41M) |
| Depreciation & Amort. | ($6.76M) | $0.54M | $0.52M | $0.26M | $0.12M |
| Stock-Based Comp. | $44.30M | $42.15M | $67.17M | $19.77M | $14.46M |
| Change in Working Capital | $23.03M | $9.60M | ($9.43M) | $15.96M | $1.72M |
| Net Cash from Operations | ($276.39M) | ($232.32M) | ($184.17M) | ($93.84M) | ($54.58M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.49M) | ($0.51M) | ($0.90M) | ($0.80M) | ($0.34M) |
| Purchases of Investments | ($579.28M) | ($695.07M) | ($407.88M) | ($223.26M) | ($188.43M) |
| Sales of Investments | $542.21M | $466.93M | $314.53M | $108.94M | $114.40M |
| Net Cash from Investing | ($37.56M) | ($228.65M) | ($94.25M) | ($115.13M) | ($74.29M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $28.88M | $0.00M | $15.00M | $5.00M | $0.00M |
| Net Cash from Financing | $426.74M | $457.74M | $225.67M | $322.24M | $125.28M |
| Free Cash Flow | |||||
| Free Cash Flow | ($276.89M) | ($232.83M) | ($185.07M) | ($94.64M) | ($54.92M) |
| FCF Margin %(computed) | -390.81% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Viridian Therapeutics, Inc. data
About Viridian Therapeutics, Inc. (VRDN) Cash Flow Statement
Viridian Therapeutics, Inc. generated operating cash flow of ($0.28B) and free cash flow of ($0.28B) for 2025 — a FCF margin of -390.81%. Capital expenditure was ($0.00B).
Frequently asked questions
VRDN · 4 questionsViridian Therapeutics, Inc. generated free cash flow of ($0.28B) for 2025, down 18.9% year-over-year.
VRDN free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10